Inkeun Park

Closest collaborators

The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Kyu‐pyo Kim · 4 shared papers, 2024–2026 · strength 0.76
   • Paper Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SAB… DOI 10.1245/s10434-026-19762-3↗
   • Paper Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancr… DOI 10.1016/j.ejca.2024.114194↗
   • Paper Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer. DOI 10.1097/js9.0000000000001389↗
2. Baek‐Yeol Ryoo · 4 shared papers, 2024–2026 · strength 0.76
   • Paper Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SAB… DOI 10.1245/s10434-026-19762-3↗
   • Paper Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancr… DOI 10.1016/j.ejca.2024.114194↗
   • Paper Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer. DOI 10.1097/js9.0000000000001389↗
3. Changhoon Yoo · 4 shared papers, 2024–2026 · strength 0.76
   • Paper Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SAB… DOI 10.1245/s10434-026-19762-3↗
   • Paper Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancr… DOI 10.1016/j.ejca.2024.114194↗
   • Paper Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer. DOI 10.1097/js9.0000000000001389↗
4. Hyehyun Jeong · 3 shared papers, 2024–2026 · strength 0.60
   • Paper Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SAB… DOI 10.1245/s10434-026-19762-3↗
   • Paper Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancr… DOI 10.1016/j.ejca.2024.114194↗
   • Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
5. Tae Jun Song · 3 shared papers, 2024–2026 · strength 0.60
   • Paper Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SAB… DOI 10.1245/s10434-026-19762-3↗
   • Paper Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancr… DOI 10.1016/j.ejca.2024.114194↗
   • Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
6. Dongwook Oh · 3 shared papers, 2024–2026 · strength 0.60
   • Paper Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SAB… DOI 10.1245/s10434-026-19762-3↗
   • Paper Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancr… DOI 10.1016/j.ejca.2024.114194↗
   • Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
7. Ki Byung Song · 3 shared papers, 2024–2026 · strength 0.58
   • Paper Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SAB… DOI 10.1245/s10434-026-19762-3↗
   • Paper Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer. DOI 10.1097/js9.0000000000001389↗
   • Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
8. Dae Wook Hwang · 3 shared papers, 2024–2026 · strength 0.58
   • Paper Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SAB… DOI 10.1245/s10434-026-19762-3↗
   • Paper Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer. DOI 10.1097/js9.0000000000001389↗
   • Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
9. Song Cheol Kim · 3 shared papers, 2024–2026 · strength 0.58
   • Paper Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SAB… DOI 10.1245/s10434-026-19762-3↗
   • Paper Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer. DOI 10.1097/js9.0000000000001389↗
   • Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
10. Woohyung Lee · 2 shared papers, 2024–2026 · strength 0.42
    • Paper Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SAB… DOI 10.1245/s10434-026-19762-3↗
    • Paper Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer. DOI 10.1097/js9.0000000000001389↗
11. Jin‐hong Park · 2 shared papers, 2024–2026 · strength 0.41
    • Paper Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SAB… DOI 10.1245/s10434-026-19762-3↗
    • Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
12. Do Hyun Park · 2 shared papers, 2024 · strength 0.35
    • Paper Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancr… DOI 10.1016/j.ejca.2024.114194↗
    • Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
13. Yejong Park · 2 shared papers, 2024 · strength 0.33
    • Paper Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer. DOI 10.1097/js9.0000000000001389↗
    • Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
14. Bong Jun Kwak · 2 shared papers, 2024 · strength 0.33
    • Paper Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer. DOI 10.1097/js9.0000000000001389↗
    • Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
15. Seung‐Mo Hong · 2 shared papers, 2018–2024 · strength 0.26
    • Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
    • Paper FGFR1 expression defines clinically distinct subtypes in pancreatic cancer. DOI 10.1186/s12967-018-1743-9↗
16. Seung Soo Lee · 1 shared paper, 2026 · strength 0.25
    • Paper Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SAB… DOI 10.1245/s10434-026-19762-3↗
17. Zev A. Wainberg · 1 shared paper, 2024 · strength 0.18
    • Paper Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancr… DOI 10.1016/j.ejca.2024.114194↗
18. Choong‐kun Lee · 1 shared paper, 2024 · strength 0.18
    • Paper Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancr… DOI 10.1016/j.ejca.2024.114194↗
19. Hye Jin Choi · 1 shared paper, 2024 · strength 0.18
    • Paper Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancr… DOI 10.1016/j.ejca.2024.114194↗
20. Dae Young Zang · 1 shared paper, 2024 · strength 0.18
    • Paper Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancr… DOI 10.1016/j.ejca.2024.114194↗
21. Sung‐Hoon Moon · 1 shared paper, 2024 · strength 0.18
    • Paper Liposomal irinotecan, oxaliplatin, and S-1 as first-line therapy for patients with locally advanced or metastatic pancr… DOI 10.1016/j.ejca.2024.114194↗
22. Min Kyu Sung · 1 shared paper, 2024 · strength 0.17
    • Paper Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer. DOI 10.1097/js9.0000000000001389↗
23. Eunsung Jun · 1 shared paper, 2024 · strength 0.17
    • Paper Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer. DOI 10.1097/js9.0000000000001389↗
24. Dong Wan Seo · 1 shared paper, 2024 · strength 0.16
    • Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗
25. Hyunseok Yoon · 1 shared paper, 2024 · strength 0.16
    • Paper Clinical outcomes of second-line therapy following disease progression on first-line modified FOLFIRINOX for borderline… DOI 10.1016/j.pan.2024.02.004↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.